Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb’s CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.
Subscribe to our email newsletter
YERVOY is a recombinant, human monoclonal antibody that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4), a negative regulator of T-cell activation.
The US Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.
Under the agreement, the two companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination.
If appropriate, the companies may conduct further development of the combination.
The agreement represents an important cross-company collaboration exploring the potential role of this regimen in the treatment of metastatic melanoma.